查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600140

男性不孕症市場：按測試、治療類型和最終用戶分類 - 2025-2030 年全球預測

Male Infertility Market by Test (Computer-Assisted Semen Analysis, DNA Fragmentation Technique, Microscopic Examination), Treatment Type (Assisted Reproductive Technologies & Surgery, Medication), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年男性不孕症市場價值為37.7億美元，預計2024年將達到40.9億美元，複合年成長率為8.94%，到2030年將達到68.8億美元。

男性不孕症市場的範圍包括旨在解決男性生殖問題因素的各種診斷和治療程序。男性不孕症被定義為無法在有生育能力的女性伴侶中誘導懷孕，主要是由於精子產量低、精子功能異常或精子輸送受阻。由於年齡、生活方式因素和環境暴露，全球範圍內不孕症的盛行率日益增加，因此需要解決男性不孕症問題。應用範圍從精液分析和荷爾蒙評估等診斷測試到藥物、手術和輔助生殖技術 (ART) 等治療，包括體外受精 (IVF) 和顯微授精 (ICSI)。最終用途包括醫療保健提供者、生育診所和研究機構，以從診斷工具和治療性介入的進步中受益。

主要市場統計
基準年[2023] 37.7億美元
預測年份 [2024] 40.9億美元
預測年份 [2030] 68.8億美元
複合年成長率（%） 8.94%

根據市場洞察，人們對不孕症治療的認知和社會接受度的提高正在增加對男性不孕症治療的需求。影響成長的關鍵因素包括診斷平台的技術創新和抗逆轉錄病毒療法的廣泛應用。個人化醫療方法存在潛在的治療機會，可以根據基因圖譜最佳化治療計劃並提高成功率。然而，它面臨著高昂的治療費用、有限的保險範圍以及與男性不孕症相關的社會文化恥辱等挑戰，這可能會阻礙市場的成長。創新可能會在非侵入性診斷技術的開發和針對特定分子途徑的新藥的尋找中得到發展。此外，整合數位健康平台可以簡化流程並提高病人參與。

男性不孕症市場正在演變成一個技術主導的領域，為研究主導的公司引入尖端解決方案提供了巨大的機會。投資於教育宣傳活動以減少男性不孕症的恥辱和降低成本障礙的技術的公司將能夠佔領重要的市場佔有率。解決這些限制，特別是透過與醫療保健支付者和倡導團體建立策略夥伴關係，可以促進市場擴張並促進創新。

市場動態：揭示快速發展的男性不孕症市場的關鍵市場洞察

供需的動態交互作用正在改變男性不孕市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 提高對男性不孕症的認知與教育
    • 由於生活型態相關因素，男性不孕症盛行率增加
    • 透過改善男性不孕症診斷和治療服務的機會來擴大醫療基礎設施
  • 市場限制因素
    • 男性不孕症治療高成本
  • 市場機會
    • 透過量身定做的治療實現個人化醫療的趨勢日益增強
    • 基因編輯技術的進步
  • 市場問題
    • 男性不孕症治療保險範圍的限制

波特五力：駕馭男性不孕症市場的策略工具

波特的五力架構是了解男性不孕症市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解男性不孕症市場的外部影響

外部宏觀環境因素在塑造男性不孕症市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解男性不孕症市場的競爭格局

男性不孕症市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：男性不孕症市場供應商績效評估

FPNV定位矩陣是評估男性不孕症市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製男性不孕症市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，男性不孕症市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高對男性不孕症的認知與教育
      • 由於生活型態相關因素，男性不孕症盛行率增加
      • 擴大醫療基礎設施並改善男性不孕症診斷和治療服務的可近性
    • 抑制因素
      • 男性不孕症治療費用高昂
    • 機會
      • 透過客製化治療計劃實現個人化醫療的趨勢正在擴大。
      • 基因編輯技術的進步
    • 任務
      • 男性不孕症治療的保險範圍有限。
  • 市場區隔分析
    • 檢測：全面且準確的評估增加了電腦輔助精液分析的應用
    • 最終用戶：專業化和專業知識將增加生育中心男性不孕症檢測的採用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 男性不孕市場：通過測試

  • 介紹
  • 電腦輔助精液分析
  • DNA分割技術
  • 顯微鏡檢查
  • 氧化壓力分析
  • 精子聚集
  • 精子穿透試驗

第7章男性不孕市場：依治療類型

  • 介紹
  • 輔助生殖技術與手術
  • 藥物治療

第8章 男性不孕市場：依最終用戶分類

  • 介紹
  • 不孕不孕治療中心
  • 醫院/診所
  • 研究所

第9章美洲男性不孕市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太男性不孕市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲男性不孕症市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Birla Fertility & IVF 收購 ARMC IVF，以提高不孕症治療的可近性和品質
    • Maven Clinic 透過新的男性不孕症支持和擴大的虛擬護理來促進生育計劃
    • 那格浦爾 ICMR 開發突破性套件來識別男性不孕症的遺傳原因
  • 戰略分析和建議

公司名單

  • Aarti Medicals Pvt. Ltd.
  • Adorefem
  • Andrology Solutions
  • Bayer AG
  • CinnaGen Co.
  • Cipla Limited
  • Dallas IVF
  • Ferring Global
  • Gladfem by Zoic Group
  • Glenmark Pharmaceuticals Limited
  • HCA International Limited
  • Intas Pharmaceuticals Ltd.
  • Male Fertility & Sexual Medicine Specialists
  • Maze Laboratories
  • Merck KGaA
  • Midwest Fertility Specialists
  • NTMIC Sperm Lab
  • Oasis Fertility
  • SCSA Diagnostics, Inc.
  • Shady Grove Fertility
  • Sun Pharmaceutical Industries Limited
  • Theramex
  • Vitrolife Sweden AB
  • Winfertility
  • Zydus Lifesciences Limited
Product Code: MRR-43286DA08074

The Male Infertility Market was valued at USD 3.77 billion in 2023, expected to reach USD 4.09 billion in 2024, and is projected to grow at a CAGR of 8.94%, to USD 6.88 billion by 2030.

The scope of the male infertility market encompasses various diagnostic and treatment procedures designed to address factors contributing to male reproductive issues. Male infertility is defined as the inability to cause pregnancy in a fertile female partner, primarily due to low sperm production, abnormal sperm function, or blockages that prevent sperm delivery. The necessity of addressing male infertility arises from the increasing prevalence of infertility cases globally, driven by age, lifestyle factors, and environmental exposures. Its applications range from diagnostic testing, such as semen analysis and hormonal evaluations, to treatments like medication, surgery, and assisted reproductive technologies (ART) including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). The end-use scope extends to healthcare providers, fertility clinics, and research institutions, which benefit from advancements in diagnostic tools and therapeutic interventions.

KEY MARKET STATISTICS
Base Year [2023] USD 3.77 billion
Estimated Year [2024] USD 4.09 billion
Forecast Year [2030] USD 6.88 billion
CAGR (%) 8.94%

Market insights reveal a growing demand for male infertility treatments attributed to increased awareness and societal acceptance of fertility health. Key factors influencing growth include technological innovations in diagnostic platforms and the broader availability of ARTs. There exists potential opportunities in personalized medicine approaches, which can optimize treatment plans based on genetic profiling, improving success rates. However, the market faces challenges such as high treatment costs, limited insurance coverage, and the socio-cultural stigmatization associated with male infertility, which may impede growth. Innovation can thrive in the development of non-invasive diagnostic techniques and the exploration of novel pharmaceuticals targeting specific molecular pathways. Furthermore, integrating digital health platforms could streamline processes and enhance patient engagement.

The male infertility market is evolving into a technologically-driven domain that provides a significant opportunity for research-driven companies to introduce cutting-edge solutions. Companies that invest in educational campaigns to destigmatize male infertility and in technologies that reduce cost barriers will be well-positioned to capture a substantial market share. Addressing these limitations, particularly by forming strategic partnerships with healthcare payers and advocacy groups, can catalyze market expansion and foster innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Male Infertility Market

The Male Infertility Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing awareness and education about male infertility
    • Increased prevalence of male infertility cases due to lifestyle-related factors
    • Expanding healthcare infrastructure with enhanced accessibility to male infertility diagnostic and treatment services
  • Market Restraints
    • High costs associated with male infertility treatments
  • Market Opportunities
    • Growing trend of personalized medicine with tailored treatment plans
    • Technological advancements in gene-editing
  • Market Challenges
    • Limited insurance coverage for male infertility treatments

Porter's Five Forces: A Strategic Tool for Navigating the Male Infertility Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Male Infertility Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Male Infertility Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Male Infertility Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Male Infertility Market

A detailed market share analysis in the Male Infertility Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Male Infertility Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Male Infertility Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Male Infertility Market

A strategic analysis of the Male Infertility Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Male Infertility Market, highlighting leading vendors and their innovative profiles. These include Aarti Medicals Pvt. Ltd., Adorefem, Andrology Solutions, Bayer AG, CinnaGen Co., Cipla Limited, Dallas IVF, Ferring Global, Gladfem by Zoic Group, Glenmark Pharmaceuticals Limited, HCA International Limited, Intas Pharmaceuticals Ltd., Male Fertility & Sexual Medicine Specialists, Maze Laboratories, Merck KGaA, Midwest Fertility Specialists, NTMIC Sperm Lab, Oasis Fertility, SCSA Diagnostics, Inc., Shady Grove Fertility, Sun Pharmaceutical Industries Limited, Theramex, Vitrolife Sweden AB, Winfertility, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Male Infertility Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test, market is studied across Computer-Assisted Semen Analysis, DNA Fragmentation Technique, Microscopic Examination, Oxidative Stress Analysis, Sperm Agglutination, and Sperm Penetration Assay.
  • Based on Treatment Type, market is studied across Assisted Reproductive Technologies & Surgery and Medication.
  • Based on End User, market is studied across Fertility Centers, Hospitals & Clinics, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing awareness and education about male infertility
      • 5.1.1.2. Increased prevalence of male infertility cases due to lifestyle-related factors
      • 5.1.1.3. Expanding healthcare infrastructure with enhanced accessibility to male infertility diagnostic and treatment services
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with male infertility treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing trend of personalized medicine with tailored treatment plans
      • 5.1.3.2. Technological advancements in gene-editing
    • 5.1.4. Challenges
      • 5.1.4.1. Limited insurance coverage for male infertility treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Test: Rising application of computer-assisted semen analysis owing to comprehensive and accurate assessments
    • 5.2.2. End User: Increasing incorporation of male fertility tests in fertility centers due to specialization and expertise
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Male Infertility Market, by Test

  • 6.1. Introduction
  • 6.2. Computer-Assisted Semen Analysis
  • 6.3. DNA Fragmentation Technique
  • 6.4. Microscopic Examination
  • 6.5. Oxidative Stress Analysis
  • 6.6. Sperm Agglutination
  • 6.7. Sperm Penetration Assay

7. Male Infertility Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Assisted Reproductive Technologies & Surgery
  • 7.3. Medication

8. Male Infertility Market, by End User

  • 8.1. Introduction
  • 8.2. Fertility Centers
  • 8.3. Hospitals & Clinics
  • 8.4. Research Institutes

9. Americas Male Infertility Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Male Infertility Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Male Infertility Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Birla Fertility & IVF Acquires ARMC IVF to Improve Accessibility and Quality of Infertility Treatment
    • 12.3.2. Maven Clinic Enhances Fertility Program with New Male Infertility Support and Expanded Virtual Care
    • 12.3.3. ICMR Nagpur Develops Breakthrough Kit to Identify Genetic Causes of Male Infertility
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aarti Medicals Pvt. Ltd.
  • 2. Adorefem
  • 3. Andrology Solutions
  • 4. Bayer AG
  • 5. CinnaGen Co.
  • 6. Cipla Limited
  • 7. Dallas IVF
  • 8. Ferring Global
  • 9. Gladfem by Zoic Group
  • 10. Glenmark Pharmaceuticals Limited
  • 11. HCA International Limited
  • 12. Intas Pharmaceuticals Ltd.
  • 13. Male Fertility & Sexual Medicine Specialists
  • 14. Maze Laboratories
  • 15. Merck KGaA
  • 16. Midwest Fertility Specialists
  • 17. NTMIC Sperm Lab
  • 18. Oasis Fertility
  • 19. SCSA Diagnostics, Inc.
  • 20. Shady Grove Fertility
  • 21. Sun Pharmaceutical Industries Limited
  • 22. Theramex
  • 23. Vitrolife Sweden AB
  • 24. Winfertility
  • 25. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. MALE INFERTILITY MARKET RESEARCH PROCESS
  • FIGURE 2. MALE INFERTILITY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MALE INFERTILITY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MALE INFERTILITY MARKET SIZE, BY TEST, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MALE INFERTILITY MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MALE INFERTILITY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MALE INFERTILITY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MALE INFERTILITY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MALE INFERTILITY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MALE INFERTILITY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MALE INFERTILITY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MALE INFERTILITY MARKET DYNAMICS
  • TABLE 7. GLOBAL MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MALE INFERTILITY MARKET SIZE, BY COMPUTER-ASSISTED SEMEN ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MALE INFERTILITY MARKET SIZE, BY DNA FRAGMENTATION TECHNIQUE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPIC EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MALE INFERTILITY MARKET SIZE, BY OXIDATIVE STRESS ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MALE INFERTILITY MARKET SIZE, BY SPERM AGGLUTINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MALE INFERTILITY MARKET SIZE, BY SPERM PENETRATION ASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGIES & SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES MALE INFERTILITY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. MALE INFERTILITY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. MALE INFERTILITY MARKET, FPNV POSITIONING MATRIX, 2023